Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study
Article in Cancer Communications (February 2024)
The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.
Article in Cancer Communications (February 2024)
Article in Chinese Medical Journal (November 2023)
Article in Annals of Oncology (October 2023)